Skip to main content
Premium Trial:

Request an Annual Quote

USPTO Publishes One Patent, Three Patent Applications Related to RNAi: Nov 20, 2008

Premium
Title: Interfering RNA Molecules
 
Number: 7,452,987
 
Filed: Aug. 5, 2003
 
Lead Inventor: Klaus Giese, Silence Therapeutics
 
The invention, the patent’s abstract states, “is related to a ribonucleic acid comprising a double-stranded structure [comprising] … a first strand and a second strand, whereby the first strand comprises a first stretch of contiguous nucleotides and whereby said first stretch is at least partially complementary to a target nucleic acid, and the second strand comprises a second stretch of contiguous nucleotides whereby said second stretch is at least partially identical to a target nucleic acid.” The abstract adds that the dsRNA of the invention is blunt-ended.
 

 
Title: Compositions for Treating Respiratory Viral Infections and Their Use
 
Number: 20080279920
 
Filed: Nov. 4, 2005 PCT Filed: Nov. 4, 2005
 
Lead Inventor: Qingquan Tang, Intradigm
 
“The invention provides siRNA compositions that interfere with viral replication in respiratory viral infections, including respiratory syncytial virus and avian influenza A [such as] the H5N1 strain,” the patent application’s abstract states. “The invention further provides uses of the siRNA compositions to inhibit expression of viral genes in respiratory virus-infected cells, and to uses in the treatment of respiratory virus infections in a subject. Generally the invention provides polynucleotide that includes a first nucleotide sequence of 15 to 30 bases that targets the genome of a respiratory syncytial virus or an influenza A virus, a complement thereof, a double-stranded polynucleotide or a hairpin polynucleotide. Additionally the invention provides vectors, cells, and pharmaceutical compositions containing siRNA sequences.”
 

 
Title: Oligoribonucleotide Inhibiting Growth of Tumor Cells and Method Therefore
 
Number: 20080280359
 
Filed: June 20, 2005 PCT Filed: June 20, 2005
 
Lead Inventor: Michinari Hamaguchi, Japan Science and Technology Agency
 
According to the patent application’s abstract, NEK2 kinase … is expressed specifically in tumor cells such as bile duct carcinoma cells, and … repression of the expression of NEK2 kinase by the use of RNA interference method [leads] to inhibition of the growth of the tumor cells.”
 
The invention comprises “a cytostatic agent for bile duct carcinoma and [other cancers] containing an oligoribonucleotide [with] a segment of bases identical or complementary to less than 30 consecutive bases of nucleotide sequence of [the NEK2 gene] … or [a] double-stranded RNA composed of the oligoribonucleotides.”
 

 
Title: Structures of Active Guide RNA Molecules and Method of Selection
 
Number: 20080280848
 
Filed: Oct. 27, 2006 PCT Filed: Oct. 27, 2006
 
Lead Inventor: Volker Patzel, Max Planck Institute for Infection Biology
 

The invention, the patent application’s abstract states, “relates to methods and compositions for modulating RNA silencing efficiency by providing selective RISC formation. The … invention also relates to methods for identifying nucleic acids and/or determining their structures.”

The Scan

Highly Similar

Researchers have uncovered bat viruses that are highly similar to SARS-CoV-2, according to Nature News.

Gain of Oversight

According to the Wall Street Journal, the Biden Administration is considering greater oversight of gain-of-function research.

Lasker for mRNA Vaccine Work

The Scientist reports that researchers whose work enabled the development of mRNA-based vaccines are among this year's Lasker Award winners

PLOS Papers on Causal Variant Mapping, Ancient Salmonella, ALK Fusion Test for NSCLC

In PLOS this week: MsCAVIAR approach to map causal variants, analysis of ancient Salmonella, and more.